Elsevier, Psychoneuroendocrinology, (66), p. 101-110
DOI: 10.1016/j.psyneuen.2015.12.024
Full text: Download
Second generation antipsychotics, like olanzapine (OLZ), have become the first line drug treatment for patients with schizophrenia. However, OLZ treatment is often associated with body weight (BW) gain and metabolic derangements. Therefore, the search for prospective markers for OLZ's negative side effects as well as adjunctive treatments to inhibit these has been of major interest.